Showing results (201-210 of 9,897) with videos related to

Sort By:
Pageof 990
Bone Marrow Transplantation|September 20, 2019
Posttransplantation cyclophosphamide vs. antithymocyte globulin as GVHD prophylaxis for mismatched unrelated hematopoietic stem cell transplantationCharlotte Nykolyszyn, Angela Granata, Thomas Pagliardini, et al.
Bone Marrow Transplantation|September 20, 2019
The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based reviewMario Tiribelli, Francesca Palandri, Emanuela Sant'Antonio, et al.
Bone Marrow Transplantation|August 22, 2019
Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restrictionRichard J O'Reilly, Susan Prockop, Aisha Hasan, et al.
Bone Marrow Transplantation|August 22, 2019
The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemiaElad Jacoby
Bone Marrow Transplantation|August 22, 2019
HLA-haploidentical hematopoietic stem cell transplantation in pediatric patients with hemoglobinopathies: current practice and new approachesLena Oevermann, Johannes H Schulte, Patrick Hundsdörfer, et al.
Bone Marrow Transplantation|August 22, 2019
Combined kidney and hematopoeitic cell transplantation to induce mixed chimerism and toleranceRobert Lowsky, Samuel Strober
Bone Marrow Transplantation|August 22, 2019
Adoptive cell therapy using engineered natural killer cellsKatayoun Rezvani
Bone Marrow Transplantation|September 29, 2019
Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working PartyAbdul Hamid Bazarbachi, Rama Al Hamed, Myriam Labopin, et al.
Bone Marrow Transplantation|October 3, 2019
Cubic splines to model relationships between continuous variables and outcomes: a guide for cliniciansJ Gauthier, Q V Wu, T A Gooley
Bone Marrow Transplantation|January 16, 2021
Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trialR Pettengell, R Uddin, A Boumendil, et al.
Pageof 990